Sex: F
Vaccine: COVID19
Symptoms: Neurological symptom, Respiratory rate, Tilt table test
Clinical narrative: Band like tightness at T4 level, paresthesia in upper limbs with fasciculations, heaviness with fatiguability in upper limbs; This is a literature report.  An adult female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history included: "covid-19" (unspecified if ongoing), notes: Probable. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE), for COVID-19 immunization. The following information was reported: NEUROLOGICAL SYMPTOM (medically significant), 3 days after the suspect product(s) administration, outcome "unknown", described as "Band like tightness at T4 level, paresthesia in upper limbs with fasciculations, heaviness with fatiguability in upper limbs". The patient underwent the following laboratory tests and procedures: Blood pressure measurement: Unknown results; Heart rate: Unknown results; anti AchR: negative; Normal; negative; Unknown results; Magnetic resonance imaging: Normal brain, cervical and thoracic spinal cord; Neurological examination: normal; Respiratory rate: unknown; Tilt table test: Unknown results. Clinical course was reported as, Patient history of COVID-19 was probable, history of autoimmune diseases was unknown. Time from vaccination to any symptoms was 16 hours, patient had symptom of fiver and myalgia at onset. Onset of neurological symptoms was 3 days.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: As there is limited information in the case provided, the causal association be-tween the event and the suspect drug cannot be excluded. The case will be reas-sessed once new information is available.  The impact of this report on the benefit-risk profile of the Pfizer product and on the conduct of the study is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate. ,Linked Report(s) : US-PFIZER INC-202200764685 Same article/ drug and different patient/event;US-PFIZER INC-202200764687 Same article/ drug and different patient/event;US-PFIZER INC-202200764688 Same article/ drug and different patient/event;US-PFIZER INC-202200764694 Same article/ drug and different patient/event;US-PFIZER INC-202200764690 Same article/ drug and different patient/event;US-PFIZER INC-202200764692 Same article/ drug and different patient/event;US-PFIZER INC-202200764693 Same article/ drug and different patient/event;US-PFIZER INC-202200764689 Same article/ drug and different patient/event;US-PFIZER INC-202200764686 Same article/patient different drug/event.;US-PFIZER INC-202200764691 Same article/ drug/ event and different patient;US-PFIZER INC-202200764693 Same article/patient different drug/event;US-PFIZER INC-202200764687 Same article/patient different drug/event.;US-PFIZER INC-202200764688 Same article/patient different drug/event.;US-PFIZER INC-202200733031 same article/drug and different patient/event;US-PFIZER INC-202200764692 Same article/drug and different event and patient.;US-PFIZER INC-202200764689 Same article/ drug and different patient/event;US-PFIZER INC-202200764694 Same article/patient different drug/event.